Varianta

Quick links to important sections

Varianta

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Varianta

Varianta is a prescription medicine presented as an oral tablet that belongs to the Combined Oral Contraceptive (COC) class. Its primary therapeutic purpose is the effective, reversible prevention of pregnancy in women of reproductive potential. The drug is a fixed-dose combination product containing two synthetic steroid hormones—an estrogen and a progestin—which work together to achieve their contraceptive effect.


Quick Facts

Property Description
Active ingredients Ethinyl Estradiol and Gestodene
Form Oral tablets
Pharmacological class Combined Oral Contraceptive (COC)
Common use Contraception (Pregnancy prevention)
Origin Synthetic (Steroid hormones)

Composition and Type

Varianta is classified as an Estrogen-Progestin Combination, placing it within the high-level pharmacological class of Combined Oral Contraceptives. The drug's active ingredients are Ethinyl Estradiol and Gestodene. Gestodene is a third-generation synthetic progestin characterized by a specific profile of hormonal activity. The use of this specific progestin combined with Ethinyl Estradiol represents a clinically recognized formulation strategy for fertility control.


Main Purpose and Authoritative Basis

The singular, overarching purpose of Varianta is to offer reliable, daily contraception for the user. As a COC, this medication is recognized for its role in public health and the prevention of unintended pregnancy. By consistently supplying synthetic hormones, Varianta suppresses the body's natural cycle and creates a physiological barrier to conception.

Regulatory References

  1. Combined oral contraceptive pill, WHO

What side effects are possible with Varianta?

Varianta: Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety information for Varianta, strictly based on regulatory documents from governmental authorities like the EMA and FDA.

Adverse Reaction Scope

Adverse reactions associated with Varianta are generally classified by their frequency and the body systems they affect, using standardized terminology like the MedDRA System Organ Class (SOC). Frequencies are typically assigned as Very Common (ge 1/10), Common (ge 1/100 to < 1/10), Uncommon, or Rare, which helps to frame the likelihood of an event occurring.

Common Adverse Reactions

The most frequently reported adverse reactions often involve the gastrointestinal system and general systemic symptoms. For example, some products in this class show a high incidence of nausea and vomiting early in the treatment course. Flu-like symptoms, such as fever and fatigue, are also frequently observed, and may be most noticeable upon initiation of therapy before decreasing over time.

Serious and Clinically Significant Adverse Reactions

Serious adverse reactions are defined as events that result in death, are life-threatening, require hospitalization, or lead to persistent disability. Clinically significant reactions documented for Varianta or related compounds include severe reactions like anaphylaxis (a severe allergic reaction) and pulmonary undesirable effects, which may rarely progress to life-threatening conditions such as Acute Respiratory Distress Syndrome (ARDS) or interstitial pneumonia. Other serious events noted in regulatory literature include thrombocytopoenia and tumour haemorrhage.

Safety Restrictions and Monitoring

Contraindications are formal restrictions stating conditions where the drug must not be used due to unacceptable risk. The prescribing information includes Warnings and Precautions sections detailing situations that require particular caution or medical monitoring. This may include mandatory laboratory testing to detect specific serious adverse reactions (e.g., blood dyscrasias, liver enzyme elevations) before they become irreversible. Safety considerations for specific groups, such as patients with pre-existing hepatic impairment or certain cardiovascular conditions, are also detailed in the official regulatory texts.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory guidance for Varianta, a combined oral contraceptive (COC) containing Ethinyl Estradiol and Gestodene, provides documented information on the manifestations and required emergency response following acute overdose.

Documented Overdose Manifestations

Symptoms of acute overdose are generally described as mild and are not likely to be life-threatening. The most frequently reported signs involve the gastrointestinal and reproductive systems:

  • Nausea and Vomiting
  • Withdrawal bleeding (or heavy vaginal bleeding) in females
  • Less common symptoms include drowsiness and breast tenderness.

Withdrawal bleeding is a specific hormonal effect that may occur in females who have taken an overdose, including pre-menarcheal girls.

Mandatory Emergency Actions

It is officially mandated that you seek immediate medical help/advice or contact Poison Control immediately if an overdose is suspected or confirmed. This action is required to receive prompt professional assessment and guidance.

Overdose Management Classification

Management of Varianta overdose is classified as symptomatic and supportive. Regulatory documentation confirms that no specific antidote is known. Clinical observation and monitoring of vital signs may be required if the overdose necessitates emergency room evaluation.


This official information establishes that while acute overdose is typically self-limiting, the mandate to seek immediate medical attention remains the required procedure to ensure proper supportive care and monitoring are administered according to medical standards.

Therapeutic Uses of Varianta

What Varianta Treats: Main Uses and Benefits

The primary purpose of this medication, which belongs to the combined oral contraceptive (COC) class, is to provide reliable and reversible prevention of pregnancy in women of reproductive potential. In addition to contraception, medications in this class are commonly used to help with various gynecological and hormonal concerns, extending their therapeutic scope.


This medication is considered relevant for managing symptoms that interfere with daily functioning across key therapeutic domains, including the management of severe menstrual cramping (dysmenorrhea), excessive blood loss (menorrhagia), moderate acne vulgaris, and the severe symptoms associated with Premenstrual Dysphoric Disorder (PMDD). By addressing these symptom clusters, Varianta contributes to improved day-to-day comfort during symptomatic periods and may assist with maintaining functional stability. The overall therapeutic benefit may be described simply by patients as:

“...providing support that helps ease the overall symptom burden.”

For patients experiencing irregular or episodic periods, this medication is commonly used to help with establishing a consistent bleeding pattern, which may assist with cycle management. Furthermore, long-term use in these contexts is associated with a secondary protective benefit, as it is relevant for easing symptoms across domains that have an association with a reduction in the risk of developing ovarian and endometrial cancers.


Quick Fact: Relief for Menstrual Distress

Symptom Domain General Benefit
Severe Cramping (Dysmenorrhea) Helps address physical discomfort and strain.
Excessive Bleeding (Menorrhagia) Supports functional stability and cycle management.
Hormonal Acne (Moderate) Contributes to easing the physical symptom burden.

Regulatory References

  1. NIH MedlinePlus overview of combination birth control pills

Eligibility and Restrictions for Use

Who Can and Cannot Use Varianta?

Varianta, a Combined Oral Contraceptive (COC), is approved for use by females of reproductive potential, including adolescents post-menarche, seeking pregnancy prevention. Eligibility is strictly defined by government regulatory documents to minimize risk, primarily linked to the estrogen component.


Absolute Contraindications (Who Must Not Use Varianta)

Official labeling states that Varianta is contraindicated and must not be used by patients with or with a history of:

  • Thromboembolic Disease: History of or current venous (DVT/PE) or arterial (MI/stroke) events, or known hypercoagulopathies.
  • Cardiovascular Risk: Smokers over age 35, uncontrolled hypertension, or migraine with aura.
  • Hormone-Sensitive Conditions: Breast cancer or estrogen-sensitive neoplasia.
  • Hepatic Conditions: Severe hepatic impairment or liver tumors.
  • Pregnancy: Known or suspected pregnancy.

Population-Specific Limitations

Population Group Eligibility Status
Lactating Women Not recommended (due to potential effect on milk production).
Postpartum Must not be initiated earlier than 21 to 42 days postpartum (depending on VTE risk).
Postmenopausal Women Not indicated (use not established).

Use is also restricted before and after major surgery involving prolonged immobilization.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Varianta, a combined oral contraceptive containing Ethinyl Estradiol and Gestodene, has officially documented interaction patterns that can alter the exposure of either the contraceptive hormones or co-administered drugs. These interactions are categorized by their effect on hormone levels, clearance, or absorption.


Contraindicated Combinations

Co-administration is formally prohibited with specific Hepatitis C virus (HCV) drug regimens, including combinations containing Ombitasvir, Paritaprevir, and Ritonavir (with or without Dasabuvir). This restriction exists due to a documented and significant risk of ALT liver enzyme elevations.


Clinically Significant Pharmacokinetic Interactions

Interaction Type Interacting Substances/Class Outcome as Documented in Labels
Exposure Reduction Hepatic Enzyme Inducers (e.g., Rifampin, Phenytoin, St. John's wort) Reduced hormone plasma concentrations, potentially compromising contraceptive efficacy via CYP3A4 induction.
Exposure Increase Varianta as CYP1A2 Inhibitor (e.g., Tizanidine) Increased co-administered drug plasma concentrations (AUC up to 3.9 times) due to decreased clearance.

Timing Constraints

The co-administration of bile acid sequestrants, such as Colesevelam, must be separated by at least four hours from Varianta. This is required to prevent interference with the hormone’s absorption in the gastrointestinal tract. Individuals with hepatic impairment are noted to have a heightened risk of adverse effects from specific drug interactions due to compromised drug clearance.

Mechanism of Action

Dual Action on Neuronal Impulse Control

Varianta operates through a dual mechanism involving both Voltage-Gated Sodium Channels (VGSCs) and GABAA Receptors. This combination physically reduces excitatory signaling while simultaneously enhancing inhibitory signaling, leading to a net reduction in neuronal excitability.

Inhibiting Nerve Firing Rate

This domain focuses on VGSC inhibition. Varianta acts as a state-dependent blocker, preferentially binding to inactivated sodium channels and impeding the rapid influx of Na^+ ions. This mechanism imposes a rate-dependent electrical brake on nerve conduction, resulting in attenuated action potential frequency.

Enhancing Central Inhibitory Signals

This domain details the action on the GABAA Receptor. Varianta functions as a Positive Allosteric Modulator (PAM), increasing the efficiency of the inhibitory neurotransmitter GABA. This action increases the Cl^- influx, resulting in neuronal hyperpolarization. This process increases the threshold for neuronal discharge, modulating the inhibitory/excitatory signaling ratio in the CNS.

Dosage and Administration Information

How to use Varianta: Administration Guidelines

Varianta is an oral tablet administered in a continuous, cyclic pattern. The approved route of administration is exclusively oral, with the tablet intended to be swallowed whole, typically with water. Taking the tablet without regard to meals is generally permissible, maintaining flexibility in daily administration timing relative to food intake.

The dosing schedule is structured as a repeating 28-day cycle. This regimen involves taking one tablet daily, sequentially, where the pack typically contains 21 active hormone tablets followed by 7 inactive or placebo tablets. It is a mandatory procedural constraint that the medicine be taken once daily at the same time each day to maintain the integrity of the usage pattern.

For beginning treatment, instructions offer procedural options such as the Day 1 Start or the Sunday Start. Continuous adherence to the daily schedule is required; a new 28-day cycle must begin immediately following the completion of the prior cycle. If a dose is missed, a label-defined protocol must be consulted to determine the appropriate corrective steps based on the number of tablets missed and the timing within the cycle. No specific age-group administration rules are noted for dose adjustment within the primary user population. The entire use protocol is structured to enforce time-critical adherence to the fixed, sequential tablet order.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Varianta

Varianta is a Combined Oral Contraceptive (COC) containing Ethinyl Estradiol and Gestodene. The evidence summarized here describes the types of research that have explored the use of this medication and the broader COC class for its primary and secondary purposes. Research provides context but not individual predictions, findings describe group patterns, not personal outcomes.


Research Evidence for Contraception (Pregnancy Prevention)

The primary purpose of this medication was studied for contraception in women of reproductive age. The evidence base includes large, prospective clinical trials that monitor populations over intermediate-term durations, typically about one year or thirteen treatment cycles. Research examined specific outcomes such as the failure rate, often reported using the Pearl Index, and monitored outcomes related to the suppression of the menstrual cycle. Bioequivalence studies were evaluated in healthy women to evaluate how different versions of the medication are absorbed by the body. Research highlights that while the failure rate in controlled trials was observed in specific ranges, the failure rate reported in typical use is higher. This difference is largely due to factors like missed doses, which research describes as a factor in maintaining continuous use.


Research Evidence for Managing Menstrual Symptoms

This content will summarize studies related to conditions characterized by fluctuating or episodic manifestations and periods of heightened symptoms.

Studies on Symptoms Beyond Contraception

The use of this medication was studied for its application in conditions characterized by certain menstrual and hormonal symptoms. The evidence includes both randomized controlled trials (RCTs) and symptom relief studies that monitor patient-reported outcomes describing perceived discomfort. For Menstrual Cramping (Dysmenorrhea), research exploring how symptoms change over time has focused on the effect of the COC class on outcomes related to physical discomfort and systemic imbalance. Studies have monitored changes in the reported severity of menstrual pain. For Moderate Acne Vulgaris, the Gestodene component was studied for outcomes linked to inflammatory or irritative states of the skin. Studies monitor changes in total acne lesion counts and use global assessment scales to measure these outcomes over several treatment cycles.


Long-Term Evidence and Secondary Protective Findings

The overall COC class was studied for long-term outcomes through large-scale epidemiological cohort studies. This research, observing women over many years, monitored outcomes related to the prevalence and incidence of certain cancers, specifically ovarian and endometrial malignancies. Findings describe patterns that was associated with the long-term use of COCs. Studies report that this association was observed in studies to persist for many years after use was discontinued, but research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Varianta (FAQ)


Q: How quickly does Varianta start working after taking it?

A: Regulatory documents state that when starting the medication on certain days of your cycle, you may need to use a non-hormonal barrier method (like a condom) for the first 7 days of taking the active pills. Following this precaution is intended to minimize the risk of reduced contraceptive effectiveness during the initial period.


Q: How long do I usually need to take Varianta?

A: Official guidance indicates that the medication is generally taken in a continuous, repeating 28-day cycle for as long as continuous contraception is desired. Continuous daily use is required to maintain contraceptive effectiveness.


Q: What happens if I miss a dose of Varianta?

A: The official product information includes a specific protocol for missed doses. If a tablet is missed by less than 12 hours, protection may not be significantly reduced, and the recommendation is to take the missed tablet immediately. Missing by more than 12 hours may diminish effectiveness, and in such cases, it is necessary to follow the specific protocol outlined on the product label and potentially use a barrier method.


Q: Are there any specific foods or drinks to avoid while taking Varianta?

A: Official guidelines state that the tablet can generally be taken without regard to meals (with or without food). However, some regulatory labels for similar medications advise caution regarding grapefruit or grapefruit juice due to the potential for interaction.


Q: Is Varianta safe for older adults (seniors)?

A: According to the official prescribing information, Varianta is not indicated for use in postmenopausal women, which includes most of the senior population. It is indicated for use by females of reproductive potential, and not for postmenopausal women.


Q: Can children or teenagers use Varianta?

A: Official labeling specifies that Varianta is indicated for use by females of reproductive potential. This includes adolescents after they have started menstruating (post-menarche), provided use is medically appropriate.


Q: Is it normal to feel a slight headache when starting Varianta?

A: Yes, headache is listed in the official product information as a common or frequently reported adverse reaction associated with the use of this class of medication. If headaches are severe or persistent, the product information recommends seeking medical evaluation.


Q: Can I take Varianta if I have high blood pressure?

A: Official labeling states that Varianta is contraindicated and must not be used by women who have uncontrolled hypertension or high blood pressure with vascular disease. The product label states that women with well-controlled hypertension may require careful medical monitoring if using this medication.


Q: Does Varianta interfere with any routine blood tests?

A: Yes, official documents warn that the estrogen component of Varianta can raise the serum concentrations of certain binding globulins. This change may affect the results and interpretation of some common laboratory tests, such as those related to thyroid function.


Q: Will Varianta affect my ability to fall asleep?

A: While the label does not consistently list insomnia as a common side effect, adverse reactions related to mood changes, anxiety, and irritability are documented in the official product information.


Q: Are there any long-term health risks associated with taking Varianta?

A: The serious long-term risks documented for combined oral contraceptives include conditions like venous thromboembolism (VTE) (blood clots in the veins) and arterial thromboses (such as heart attack or stroke). Rare risks of liver tumors are also noted in the regulatory documents.


Q: Can Varianta interact with alcohol consumption?

A: The official product information does not strictly prohibit alcohol consumption with Varianta. Regulatory texts may categorize the interaction as minor, suggesting caution.


Q: Will Varianta cure my condition, or just manage the symptoms?

A: The primary indication for Varianta is pregnancy prevention. While it is sometimes used to manage symptoms of conditions like menstrual pain, it functions by regulating hormone levels and does not provide a cure for chronic medical conditions.


Q: Do people gain or lose weight while on Varianta?

A: Official adverse reaction data lists weight increased (weight gain) as a frequently reported adverse reaction observed in clinical trials for combined oral contraceptives.


Q: Is it possible to be allergic to Varianta?

A: Yes, regulatory documents list severe allergic reactions, including anaphylaxis (a severe, whole-body allergic reaction), as rare but clinically significant adverse reactions. This confirms the possibility of an allergic response to the medication.


Q: Why do some people need to take Varianta long-term?

A: The long-term use is consistent with its primary therapeutic purpose, which is the continuous prevention of pregnancy in women of reproductive potential. Continuous daily use is necessary to maintain the drug’s effectiveness.


Q: Does Varianta have any known effects on mood or anxiety?

A: Yes, official prescribing information lists mood changes, anxiety, and depression as reported adverse reactions that have been associated with the use of combined oral contraceptives.


Q: What's the typical duration of the side effects when starting Varianta?

A: For common adverse reactions, such as nausea and vomiting, regulatory documents state that these effects are often reported to decrease over time as the body adjusts to the medication after initiation of therapy.


Q: Why does Varianta sometimes need to be taken with food?

A: Although the medication can generally be taken without regard to meals, official instructions for similar products often note that taking the pill with food may help reduce upset stomach or nausea, which are common effects when starting treatment.


Q: Can Varianta make my skin more sensitive to the sun?

A: Official warnings mention that chloasma (dark patches on the skin) may occur. The product label cautions that women with this tendency should avoid exposure to the sun or ultraviolet (UV) light.


Q: Are the side effects of Varianta generally mild?

A: While the majority of documented adverse reactions are classified as Very Common or Common and are often temporary, the label also documents serious, clinically significant events (like blood clots) that are not considered mild.


Q: Can men and women use Varianta equally?

A: No. The official indications explicitly state that Varianta is intended for use by females of reproductive potential for the purpose of pregnancy prevention.


Q: Do I need to taper off Varianta, or can I stop suddenly?

A: Official use guidelines do not describe a tapering process for Varianta; use is typically stopped immediately when a contraindication occurs. Official information notes that the risk of blood clots gradually decreases after use is discontinued.


Q: What are the success rates mentioned in studies for Varianta?

A: The contraceptive efficacy is quantified in regulatory documents using the Pearl Index (failure rate). Official information highlights that the failure rates observed in typical use are generally higher than those found in controlled clinical trials.


Q: Is it okay to crush or split Varianta tablets?

A: No. The official product labeling describes the medication as an oral tablet that is intended to be swallowed whole. The instructions do not contain procedures or recommendations for breaking, crushing, or splitting the tablets.


Q: Can I take other prescription medications while on Varianta?

A: Varianta is known to interact with many drugs, particularly those that affect liver enzymes. The official label advises that interactions can occur, and it is necessary to inform a healthcare provider about all other medications being taken.


Q: Does Varianta contain gluten or common allergens?

A: The official product description lists all inactive ingredients (excipients) used in the tablet formulation. The inactive ingredients are listed in the product description, which allows checking for components like lactose or starches that may be relevant to intolerances.


Q: Is Varianta safe for people with diabetes?

A: The official product information states that women who are prediabetic or diabetic require careful monitoring, as the medication may decrease glucose tolerance. Furthermore, the drug is contraindicated in women with diabetes complicated by vascular disease.

How should Varianta be stored and disposed of?

How to Store and Dispose of Varianta

Storage and disposal requirements for Varianta tablets, a combined oral contraceptive, are strictly defined by regulatory guidance to maintain product stability and ensure environmental safety.


Mandatory Storage Conditions

Requirement Details (Based on Official Labeling)
Temperature Store at controlled room temperature; do not exceed 30 C (86 F).
Protection Keep in the original container/blister pack and protect from excessive heat, moisture, and light.
Safety Must be stored out of the sight and reach of children.

Official Disposal Requirements

Unused or expired Varianta must be disposed of according to local regulations or a formal drug take-back program. It is strictly prohibited to flush the tablets down the toilet or pour them down a drain to prevent environmental contamination by the synthetic steroid hormones.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Varianta found in:

A-Z Index: